Orchard Therapeutics
Clinical trials sponsored by Orchard Therapeutics, explained in plain language.
A biopharmaceutical company developing gene therapies for rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Gene therapy shows promise for rare fatal brain disease in kids
Disease control CompletedThis study tested a gene therapy called OTL-200 in 10 children with early-onset metachromatic leukodystrophy (MLD), a rare and severe brain disease. The treatment uses the child's own blood stem cells, modified to produce a missing enzyme, and aims to slow or stop disease progres…
Phase 2 • Sponsor: Orchard Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Gene therapy offers hope for children with rare brain disease
Disease control CompletedThis study tested a gene therapy for children with metachromatic leukodystrophy (MLD), a rare, inherited brain disease that causes severe disability and early death. The treatment uses the child's own blood stem cells, which are modified in a lab to carry a working copy of the mi…
Phase 1/2 • Sponsor: Orchard Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC